Bardoxolone data set Reata up to advance second compound toward registration

Weeks after regaining rights to cardiorenal compounds from AbbVie, Reata has reported its second pivotal trial success of the quarter, paving the way for global marketing applications for its two most advanced compounds as it awaits registrational data in follow-on indications.

On Tuesday, Reata Pharmaceuticals Inc. (NASDAQ:RETA) said bardoxolone, its first-generation NFE2L2 activator, met the primary endpoint of improving estimated glomerular filtration rate (eGFR) in the Phase III portion of the CARDINAL trial for patients chronic kidney disease (CKD) caused by Alport syndrome...